Inhibitory effect of terfenadine on Kir2.1 and Kir2.3 channels

Terfenadine is a second-generation H1-antihistamine that despite potentially can produce severe side effects it has recently gained attention due to its anticancer properties. Lately, the subfamily 2 of inward rectifier potassium channels (Kir2) has been implicated in the progression of some tumoral processes. Hence, we characterized the effects of terfenadine on Kir2.x channels expressed in HEK-293 cells. Terfenadine inhibited Kir2.3 channels with a strikingly greater potency ($IC_{50} = 1.06 \pm 0.11 \text{ μmol L}^{-1}$) compared to Kir2.1 channels ($IC_{50} = 27.8 \pm 4.8 \text{ μmol L}^{-1}$). The Kir2.3(I213L) mutant, possessing a larger affinity for phosphatidylinositol 4,5-bisphosphate (PIP$_2$) than the wild-type Kir2.3, was less sensitive to terfenadine inhibition ($IC_{50} = 13.0 \pm 2.9 \text{ μmol L}^{-1}$). Additionally, the PIP$_2$ intracellular application had largely reduced the inhibition of Kir2.1 channels by terfenadine. Our data support that Kir2.x channels are targets of terfenadine by affecting their interaction with PIP$_2$, which could be regarded as a mechanism of the antitumor properties of terfenadine.

Keywords: terfenadine, inward rectifier potassium channels, phosphatidylinositol 4,5-bisphosphate, cationic amphiphilic drugs

Terfenadine is a non-sedating second-generation H1-antihistamine formerly prescribed to treat allergic rhinitis and urticarial (1). This drug was withdrawn from the market (2) due to the risk of fatal arrhythmias (torsades de pointes and ventricular fibrillation) (3) by inhibiting several cardiac ion channels, including hERG (4), Na$_V$1.5 (5), hKv1.5 (6), and Kir3.1 (I$_{KCa3}$) (7).

Terfenadine has recently attracted attention due to important anticancer properties in different experimental models (in vitro and in vivo). This drug suppresses the spontaneous growth of neoplastic mast cells by an apoptotic mechanism (8). In addition, terfenadine triggers apoptosis in melanoma cells (9) and human hormone unresponsive prostate cancer (10). Notably, terfenadine reduces the tumor growth in breast cancer cells, including both basal cells and cells resistant to trastuzumab (11), and in resistant non-small cell lung cancer when combined with epirubicin (12).

*Correspondence; e-mail: tania@ucol.mx
The Kir2 channels subfamily is composed of four members (Kir2.1- Kir2.4) underlying an inwardly rectifying $K^+$ current (13, 14). Kir2.x channels are very important for setting and controlling the resting membrane potential of different types of cells (13). Also, these channels help to determine the action potential waveform and the excitability of cardiac myocytes and neurons (13). Interestingly, it has been shown recently that Kir2.x channels are implied in some tumoral processes. To mention a few, the expression of Kir2.1 is increased in stomach cancer cells controlling invasion and metastasis (15) and is associated with drug resistance of small-cell lung cancer (16). Kir2.2 is involved in the in vivo progression of tumors derived from PC3 cells (a human prostate adenocarcinoma) (17). In turn, Kir2.3 has been implicated in the growth and metastasis of lung adenocarcinoma (18).

As reported by previous studies, Kir channels are inhibited by several drugs with a distinctive structure, the so-called cationic amphiphilic drugs (CADs) (19). These compounds are characterized by their archetypical amphiphilic structure determined by a hydrophobic region (aliphatic or aromatic rings) and a hydrophilic moiety that includes an amino group charged at physiological pH (19). Therefore, given the terfenadine’s CAD-like type of nature (Fig. 1a) and its anti-tumoral properties, as well as the important role of Kir2.x channels in carcinogenesis, we have investigated the hypothesis that terfenadine inhibits Kir2.x channels and determined the underlying mechanism of action in this study.

EXPERIMENTAL

Drug and reagents

Terfenadine (purity > 97.5 %) was purchased from Sigma-Aldrich (USA) and dissolved in DMSO to prepare a 10 mmol L$^{-1}$ stock solution, which was diluted in the extracellular (bath) solution to final concentrations as required. L-α phosphatidylinositol 4,5-bisphosphate (PIP$_2$, (Avanti Polar Lipids, USA) was aliquoted, dried, and stored at –70 °C. Aliquots were diluted to 10 μmol L$^{-1}$ in the intracellular (pipette) solution and sonicated on ice for 15 min before application.

Cell culture and cDNA expression

We carried out the experiments in HEK-293 cells that were cultured under standard conditions in Dulbecco’s modified Eagle’s medium (Gibco, USA) supplemented with 10 % fetal bovine serum (Gibco) and 1 % antibiotic-antimycotic solution (Sigma-Aldrich) at 37 °C in a humidified incubator (5 % CO$_2$). The Lipofectamine 2000 reagent (Invitrogen, USA) was used for transiently transfecting HEK-293 cells with human cDNAs (2 μg) encoding Kir2.1, Kir2.3 (provided by C. Vandenberg from the University of California, Santa Barbara, CA, USA), or Kir2.3(I213L) channels 24 h before the experiments. The QuickChange Site-Directed Mutagenesis kit (Stratagene, USA) was employed to prepare the Kir2.3(I213L) mutant channel. DNA sequencing was used to validate the mutation. Transfected cells were identified using the green fluorescent protein (GFP), which was co-transfected with the Kir2.x cDNAs.
Fig. 1. Decrease of Kir2.1 currents produced by terfenadine. a) Chemical structure of terfenadine. b) Representative Kir2.1 current traces before and after 30 μmol L\(^{-1}\) terfenadine application. In all figures containing current traces, the inset shows the voltage protocol used to elicit the currents. Currents were normalized to that obtained at –140 mV in control conditions (the holding current is not shown). c) Mean data of the normalized current recorded at –140 mV in control conditions and during perfusion of 30 μmol L\(^{-1}\) terfenadine, plotted as a function of the perfusion time. d) The concentration-effect relationship for inhibition of Kir2.1 current at –140 mV by terfenadine. Values of IC\(_{50}\) and Hill slope (H) are mentioned in the text; n = 5.

**Electrophysiological recordings**

Macroscopic current recordings were performed at room temperature (22–24 °C) using the patch-clamp method in the whole-cell configuration. We employed the pCLAMP 9 software (Molecular Devices, USA), an Axopatch 200B amplifier (Molecular Devices) and a Digidata 1440A interface (Molecular Devices) to acquire data and generate pulses. Currents were low-pass filtered at 1 kHz and digitized at 5 kHz. Patch electrodes were fabricated from borosilicate glass (World Precision Instruments, USA) in a programmable puller (Sutter Instruments, USA). Micropipettes had tip resistances between 1.5 and 2.5 MΩ after being filled with the intracellular (pipette) solution. The extracellular (bath) solution without (control) or with terfenadine was applied using a rapid switching device (VC-77SP Warner Instruments, USA), and recordings were obtained when reaching steady-state conditions. The intracellular (pipette) solution composition was (in mmol L\(^{-1}\)): KCl, 110; HEPES, 10; K\(_4\)BAPTA, 5; K\(_2\)ATP, 5; and MgCl\(_2\), 1 (pH was adjusted to 7.2 with KOH). The extracellular (bath) solution had the following composition (in mmol L\(^{-1}\)): NaCl, 130; KCl, 4; CaCl\(_2\), 1.8; MgCl\(_2\), 1; HEPES, 10; and glucose, 10 (pH was adjusted to 7.4 with NaOH). The bath was grounded through an agar-KCl bridge. All current traces are shown as the currents sensitive to 2 mmol L\(^{-1}\) BaCl\(_2\).
Data analysis

For analyzing current recordings, we used the software pClamp 10.6 (Molecular Devices) and Origin 8 (OriginLab Corp., USA). Concentration-response curves were fitted with a Hill equation \( f = 1 / (1 + (IC_{50})/[\text{terfenadine}^H] \); where \( f \) is the fractional block of the current and \( H \) the Hill coefficient. Statistical analysis (Origin 8; OriginLab Corp.) was performed using the unpaired Student’s t-test after evaluating the normal distribution of data with the Shapiro-Wilk test. Results are expressed as mean ± SEM, and the significance of the differences was assumed at \( p < 0.05 \) (two-tailed).

RESULTS AND DISCUSSION

Terfenadine inhibits the Kir2.1 and Kir2.3 channels

In this study, we examined whether terfenadine affects Kir2.1 and Kir2.3 channels and the underlying mechanism of action. To this end, HEK-293 cells were used to express Kir2.x channels because they are a good model to study the biophysical properties of exogenous ion channels in isolation; they are easily transfected and voltage-clamped, and their small endogenous currents do not interfere with the analysis of the studied current (20). Thus, Kir2.1 and Kir2.3 currents were evaluated using a voltage-ramp protocol (3 s duration) from –140 to 0 mV every 15 s and a holding potential of –80 mV. Fig. 1b shows representative Kir2.1 current traces in control conditions and after the perfusion of 30 μmol L\(^{-1}\) terfenadine. The development of the terfenadine effect on Kir2.1 currents was slow as depicted in the time course of inhibition (Fig. 1c). Terfenadine inhibition on Kir2.1 currents increased when augmenting the drug concentration: the concentration-response relationship (measured at –140 mV) yielded an \( IC_{50} \) of 27.8 ± 4.8 μmol L\(^{-1}\) and \( H \) of 0.56 ± 0.06 (Fig. 1d).

In turn, the effect of terfenadine on Kir2.3 currents was strikingly more potent than that on Kir2.1, since ~50 % of the current was inhibited by 1 μmol L\(^{-1}\) terfenadine (Fig. 2a); although the time course was similarly slow (Fig. 2b). The \( IC_{50} \) to inhibit Kir2.3 channels

![Fig. 2. Terfenadine inhibits Kir2.3 channels. a) Illustrative recordings of Kir2.3 currents evoked in control conditions and after perfusion of 1 μmol L\(^{-1}\) terfenadine. b) Time course of development of Kir2.3 current inhibition by 1 μmol L\(^{-1}\) terfenadine at –140 mV. c) A concentration-response curve of inhibited Kir2.3 current at –140 mV; \( n = 5 \).](image-url)
was 1.06 ± 0.11 μmol L⁻¹ (H of 1.14 ± 0.14) (Fig. 2c), which is ~ 26-fold lower in comparison to that for Kir2.1. The slow time courses of inhibition and the different potency of terfenadine to inhibit Kir2.1 and Kir2.3 channels resemble those of CADs, whose mechanism of action is to interfere with the Kir channel-PIP₂ interaction (21). The effect of terfenadine on Kir2.1 and Kir2.3 channels was inversely correlated with the apparent affinity of these channels for PIP₂ (20), the lower the affinity for PIP₂, the greater the potency of terfenadine to inhibit the channel. Thus, we next proceeded to test this hypothesis considering the CAD-type nature of terfenadine.

**Kir2.3(I213L) mutant channel is less sensitive to terfenadine inhibition**

Compared to the wild-type Kir2.3, Kir2.3(I213L) mutant channel has a higher apparent affinity for PIP₂ and thus, it is less sensitive to inhibitory drugs (21). Hence, we assessed the effect of terfenadine on this mutant channel to investigate the inhibitory mechanism of this compound. Terfenadine decreased Kir2.3(I213L) currents with lesser potency (10 μmol L⁻¹ terfenadine diminished the current in ~ 50 %) (Fig. 3a) than that for wild-type Kir2.3. The time course of the terfenadine effect on Kir2.3(I213L) was also slow (Fig. 3b). An IC₅₀ of 13.0 ± 2.9 μmol L⁻¹ (H of 0.77 ± 0.16) was obtained from the concentration-response relationship (Fig. 3c), resulting ~12-fold greater than that observed for wild-type Kir2.3 channels. These data suggest that the interaction between PIP₂ and Kir2.x channels is affected by terfenadine.

Terfenadine is a basic compound with a moderate degree of lipophilicity (log D = 2.11, pKₐ = 8.6) that could interact with the hydrophobic and hydrophilic moieties of phospholipids, particularly with those negatively charged (22). Other drugs with the same characteristics inhibit Kir channels by several mechanisms, but it has been shown that such drugs mainly affect the interaction of the channels with PIP₂ (19). In this regard, it was recently reported that terfenadine inhibits Kir3.1 channels by binding to a region below the residue F137 (a pore-helix amino acid) and amid the transmembrane helices from two contiguous subunits. Binding of terfenadine to this region sterically interferes with the PIP₂-channel interaction, suggesting that this could be the mechanism of inhibition (7).

**Fig. 3. Effects of terfenadine on the mutated channel Kir2.3(I213L).** a) Normalized recordings of Kir2.3(I213L) current obtained previously and following exposure to 10 μM terfenadine. b) Time course of inhibition (at –140 mV) of Kir2.3(I213L) channels by 10 μmol L⁻¹ terfenadine. c) Terfenadine concentration plotted as a function of the Kir2.3(I213L) current inhibition at –140 mV; n = 5.
Exogenous PIP$_2$ attenuates the inhibition of Kir2.1 channels by terfenadine

To support the hypothesis that terfenadine’s mechanism of action could be by interfering with the Kir2.x channel-PIP$_2$ interaction, we performed an additional experiment by dialyzing (for 5 min in the patch pipette) exogenous PIP$_2$ before the terfenadine application in the extracellular (bath) solution in Kir2.1 expressing cells. Fig. 4a,b depicts the effect of 30 μmol L$^{-1}$ terfenadine on Kir2.1 currents in control conditions and after intracellular perfusion of 10 μmol L$^{-1}$ PIP$_2$. When PIP$_2$ was present in the patch pipette, terfenadine inhibition was reduced ~ 50 %, since the percentage inhibition at –140 mV was 24.3 ± 1.0 % ($n = 5$), compared to 45.1 ± 1.5 % ($n = 6$) in cells recorded in the absence of PIP$_2$ (Fig. 4c).

Overall, our data suggest that terfenadine targets the PIP$_2$-channel interaction to inhibit the channels. First, the drug inhibited Kir2.x channels with a slow time course, which is characteristic of this mechanism of action (19), where the drug probably inserts into the lipid membrane. Second, strengthening the interaction of the channel and PIP$_2$ (by using the Kir2.3(I213L) mutant channel) decreased the terfenadine inhibition. Third, supplying exogenous PIP$_2$ to the intracellular milieu reduced the potency of terfenadine to inhibit Kir2.1 channels. Taken together, our results support that Kir2.1 and Kir2.3 channels are inhibited by terfenadine due to the interference of the channel interaction with PIP$_2$.

Given the role of K$^+$ channels on tumoral processes, in recent years their pharmacological inhibition has been considered as a promising strategy against carcinogenesis, either by reducing the proliferation and/or decreasing the invasiveness and cell migration in different cancer cell types (23–25). Therefore, this work supports the potential application of terfenadine derivatives with fewer side effects as a part of anticancer therapy in Kir2.x expressing malignant cells, although, further studies (in vitro and in vivo) are needed to elucidate the effect of terfenadine on the malignant proliferation and metastasis of these types of tumoral cells.

CONCLUSIONS

Terfenadine was more potent to inhibit Kir2.3 than Kir2.1 channels, and the mutation Kir2.3(I213L) decreased the terfenadine effect compared to that on Kir2.3, i.e. the stronger
the affinity of the channel for PIP$_2$, the lower the potency of terfenadine to inhibit this channel. We also found that the PIP$_2$ intracellular application decreased the potency of terfenadine to inhibit Kir2.1 channels. Our results suggest that terfenadine interferes with the PIP$_2$-channel interaction. This could be an alternative mechanism contributing to the anticancer properties of terfenadine and could have a potential application in tumors where Kir2 channels have a relevant role in proliferation and metastasis.

Acknowledgments. – We are grateful to QFB Miguel Ángel Flores Virgen (Centro Universitario de Investigaciones Biomédicas de la Universidad de Colima, Colima, Col. Mexico) for the technical assistance. M. D-R. is a Postdoctoral Fellow (# 740437) of the Consejo Nacional de Ciencia y Tecnología (Conacyt, Mexico). This work was supported by SEP-Conacyt grants: CB-2010-01-153394 (to T.F.) and CB-2013-01-220546 (to J.A.S.-C.).

REFERENCES

2. F. Register, Proposal to withdraw approval of two new drug applications and one abbreviated new drug application; opportunity for a hearing. *Food and Drug Administration* [Docket No. 96N-0512], *Federal Register* [62](1997) 2–9.

323


